The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
MRI Biomarkers Program, 2025Evaluation of Neuromelanin-sensitive, Quantitative Susceptibility Mapping and Free Water Imaging as Biomarkers of Nigral Dopaminergic Dysfunction
Study Rationale: This project seeks to validate three magnetic resonance imaging biomarkers capable of detecting and monitoring the degeneration of neurons in the substantia nigra in Parkinson’s...
-
Research Grant, 2025FUN-MITO: Functional Validation of Mitochondrial Polygenic Risk Scores in the PPMI Cohort
Study Rationale: In the majority of people with Parkinson's disease (PWP), the movement disorder is not caused by mutations in a single gene. Until recently, these people were considered “sporadic”...
-
Parkinson’s Disease Therapeutics Pipeline Program, 2025Pre-clinical Development of Novel GCase Variants for Treating Parkinson’s Disease
Study Rationale: The most prevalent genetic risk factors for Parkinson’s Disease (PD) are mutations in GBA1, the gene that encodes the glucocerebrosidase (GCase) enzyme. Dysfunction of GCase leads to...
-
ASAP CRN Competitive Renewal Opportunity, 2025Senescence in Parkinson’s Disease and Related Disorders
Study Rationale: While aging is the greatest risk factor for development of Parkinson’s disease (PD), how aging promotes PD is not fully understood. Examining the role of cellular senescence, a major...
-
Cell Line, 2002Dopamine Neurons Derived from Human ES Cells
Embryonic stem (ES) cells proliferate extensively, and preliminary data show that animal ES cells can be manipulated to generate highly enriched populations of dopamine neurons that express genes...
-
Cell Line, 2002Unlimited Numbers of Purified Midbrain Dopamine Neurons from Human Embryonic Stem Cells
The fact that dopamine (DA) cells are lost specifically but other nerve cells are still intact makes Parkinson's disease (PD) uniquely amenable to cell replacement therapy. Early attempts have...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.